Showing 631-640 of 685 results for "".
- Nestle to Explore Strategic Options for Skin Health Divisionhttps://modernaesthetics.com/news/nestle-to-explore-strategic-options-for-skin-health-division/2472031/...After further analysis and consideration, the Board has come to the conclusion that the future growth opportunities of Nestlé Skin Health lie increasingly outside the Group’s strategic scope
- ASDS 2018 Survey: Close to 70 percent of Consumers Thinking About Cosmetic Treatmentshttps://modernaesthetics.com/news/asds-2018-survey-close-to-70-percent-of-consumers-are-thinking-about-cosmetic-treatments/2472034/Almost 70 percent of consumers are considering a cosmetic treatment, and more than half would prefer to pay more up front to lower their annual skin care costs, according to the 2018 American Society for Dermatologic Surgery (ASDS) Consumer Survey on Cosmeti
- Leading Plastic Surgery Groups Warn on the Risks of Brazilian Butt Liftshttps://modernaesthetics.com/news/leading-plastic-surgery-groups-warn-on-the-risks-of-brazilian-butt-lifts/2472050/Leading plastic surgery organizations are issuing a loud warning call about the risks associated with the popular Brazilian Butt Lift. “[The] procedure … has resulted in a mortality rate that is estimated to be as high as 1:3,000, greater than any other cosmetic surgery,&rdqu
- Cutera Marks 20 Years of Innovationhttps://modernaesthetics.com/news/cuter-marks-20-years-of-innovation/2472102/Cutera, Inc. is celebrating 20 years of best-in-class product innovation with continued commitment to the industry and its providers, marking the milestone at the Annual Meeting of the American Society for Laser Medicine and Surgery in Dallas. In conjunction with the 20th&nbs
- Game On: Revance Readies for Launch of their Botox Competitorhttps://modernaesthetics.com/news/game-on-revance-readies-for-launch-of-their-botox-competitor/2472111/With the advent of four new positions, Revance Therapeutics is expanding their commercialization team in anticipation of the product launc
- New ASPS Data: Minimally Invasive Aesthetic Procedures Up 200 Percent Since 2000https://modernaesthetics.com/news/new-asps-data-minimally-invasive-aesthetic-procedures-up-200-percent-since-2000/2472125/Drumroll, please… Plastic surgery is on the rise, according to the annual statistics from the American Society of Plastic
- New AAFPRS Data: Social Media Makes Lasting Impact on Industryhttps://modernaesthetics.com/news/new-aafprs-data-social-media-makes-lasting-impact-on-industry/2472141/Like it or not, the selfie and its impact on aesthetics is here to stay, and continues to have a huge effect on how we perceive and project ourselves in front of the camera and off. This is among the main findings from the annual survey of the
- Syneron Candela Becomes Private Company with Completion of Transaction with Funds Advised by Apax Partnershttps://modernaesthetics.com/news/syneron-candela-becomes-private-company-with-completion-of-transaction-with-funds-advised-by-apax-partners/2472211/Syneron Medical Ltd. announced the successful completion of its acquisition by an affiliate of funds advised by Apax Partners for $11.00 per share in cash in a transaction valued at approximately $400 million. The transacti
- Allergan CEO Calls for Consensus on Medical Aesthetic Treatment in Minorshttps://modernaesthetics.com/news/allergan-ceo-calls-for-consensus-on-medical-aesthetic-treatment-in-minors/2472213/Allergan Chairman & CEO Brent Saunders, the father of two high school-aged girls, is speaking up and out about the risks associated with offering medical aesthetic treatments to minors. In a new blog post, he writes “we must remember that anyone under the age of 18 is still matu
- Neothetics, Inc.'s Stock Tumbles Following "Unambiguous" Negative LIPO-202 Resultshttps://modernaesthetics.com/news/neothetics-incs-stock-tumbles-following-unambiguous-negative-lipo-202-results/2472217/Neothetics, Inc.’s LIPO-202 for the reduction of submental subcutaneous fat failed to demonstrate improvement on any efficacy measurements or separation from placebo in a Phase 2 proof-of-concept trial. Neothetics Inc. shares d